Makers of top-selling drugs hike prices in lockstep, and patients bear the cost - STAT
The makers of two arthritis drugs increased their prices in lockstep from 2013-2018, reflecting their clout in a market where patients suffer blinding painRead full story
One has to wonder, is this ethical?
A community of leaders, subject matter experts, and curious minds bringing nuance back to how we talk about the news.
No content overload: our editors will curate the most notable and discussion-worthy pieces for you every day.
Don’t just read the story, tell it: contribute your ideas and experience to the dialogue.